A year of changes continues for a Sarasota health company, as INVO Fertility will begin trading under the new Nasdaq ticker ...

Disclaimer: This Tournament of Champions article is based on the writer's opinion. Reader discretion is advised.

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 ...

INVO Fertility (IVF), formerly known as NAYA Biosciences (NAYA), confirmed it will begin trading under the new symbol “IVF” at the market open ...

INVO Fertility, Inc. (Nasdaq: NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, ...

Delcath Systems Inc. research and ratings by Barron's. View DCTH revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Zurich-based start-up Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

Guardant Health Inc. stock grades by Barron's. View GH fundamental and sentiment analysis powered by MarketGrader.

Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

Like many projects born out of passion, “Champions of the Golden Valley” — a feature film screening at this year’s 5Point ...

This is the first CSCO Guidelines recommendation for lisaftoclax (APG-2575), making it the only China-developed Bcl-2 inhibitor recommended in the CSCO Guidelines. This marks a milestone achieved by ...